---
title: Clinical networking results in continuous improvement of the outcome of patients
  with acute promyelocytic leukemia
date: '2024-05-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38805638/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240529181009&v=2.18.0.post9+e462414
source: Blood
description: The introduction of all-trans retinoic acid (ATRA) combined with anthracyclines
  has significantly improved the outcomes for patients with acute promyelocytic leukemia
  (APL), and this strategy remains the standard of care in countries where arsenic
  trioxide is not affordable. However, data from national registries and real-world
  databases indicate that low- and middle-income countries (LMIC) still face disappointing
  results, mainly due to high induction mortality and suboptimal management ...
disable_comments: true
---
The introduction of all-trans retinoic acid (ATRA) combined with anthracyclines has significantly improved the outcomes for patients with acute promyelocytic leukemia (APL), and this strategy remains the standard of care in countries where arsenic trioxide is not affordable. However, data from national registries and real-world databases indicate that low- and middle-income countries (LMIC) still face disappointing results, mainly due to high induction mortality and suboptimal management ...